Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Hyperthermia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Malignant Hyperthermia. Displaying page 1 of 1.
    EudraCT Number: 2015-000167-14 Sponsor Protocol Number: 105-15-201 Start Date*: 2017-02-16
    Sponsor Name:CELSION CORPORATION
    Full Title: HEAT-ACTIVATED TARGET THERAPY RADIOTHERAPY + HYPERTHERMIA + LYSO THERMOSENSITIVE LIPOSOMAL DOXORUBICIN) OF LOCALREGIONAL RELAPSE IN BREAST CANCER PATIENTS
    Medical condition: Local-Regional Relapse in Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003855-11 Sponsor Protocol Number: 025/05 Start Date*: Information not available in EudraCT
    Sponsor Name:Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze
    Full Title: Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Ge...
    Medical condition: Combination of standard chemotherapy with Gemcitabine and Cisplatin and regional hyperthermia in patients with locally advanced or metastatic pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2013-003830-34 Sponsor Protocol Number: 415-13 Start Date*: 2014-05-15
    Sponsor Name:Asklepios Fachkliniken München Gauting
    Full Title: Pleurectomy/decortication and hypterthermic intrathoracic chemotherapy compared to pleurectomy/decortication in patients with malignant pleural mesothelioma
    Medical condition: malignant pleuramesothelioma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027407 Mesothelioma malignant PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000522-58 Sponsor Protocol Number: NPM001 Start Date*: 2014-10-02
    Sponsor Name:Klinikum der Universität München
    Full Title: A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or ad...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010093-38 Sponsor Protocol Number: HyRec Start Date*: 2012-08-15
    Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler
    Full Title: Multi-institutional Phase I/II Study: Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxaliplatin combined with deep regional hyperthermia in locally advanced or recurrent rectal cancer
    Medical condition: Locally advanced primary or locally recurrent rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038051 Rectal cancer stage IV PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038046 Rectal cancer recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002872-15 Sponsor Protocol Number: 1203/12 Start Date*: 2012-09-13
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Hyperthermic intra-peritoneal chemotherapy (HIPEC) in Ovarian cancer recurrence: Randomized trial on Survival Evaluation.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005428-99 Sponsor Protocol Number: 08/0365 Start Date*: 2009-10-19
    Sponsor Name:University College London
    Full Title: A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive b...
    Medical condition: Non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005006 Bladder cancer stage 0, with cancer in situ LLT
    9.1 10005007 Bladder cancer stage 0, without cancer in situ LLT
    9.1 10005008 Bladder cancer stage I, with cancer in situ LLT
    9.1 10005009 Bladder cancer stage I, without cancer in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA